Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Status:
Recruiting
Trial end date:
2026-04-04
Target enrollment:
Participant gender:
Summary
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed
after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and
efficacy of the treatment with chidamide in combination with decitabine.